

- [ScienceWatch Home](#)
- [Inside This Month...](#)
- [Interviews](#)

Featured Interviews
 Author Commentaries
 Institutional Interviews
 Journal Interviews
 Podcasts

[Analyses](#)

Featured Analyses
 What's Hot In...
 Special Topics

[Data & Rankings](#)

Sci-Bytes
 Fast Breaking Papers
 New Hot Papers
 Emerging Research Fronts
 Fast Moving Fronts
 Research Front Maps
 Current Classics
 Top Topics
 Rising Stars
 New Entrants
 Country Profiles

[About Science Watch](#)

Methodology
 Archives
 Contact Us
 RSS Feeds


[Interviews](#)
[Analyses](#)
[Data & Rankings](#)

2008 : December 2008 : David C. Rubinsztein

EMERGING RESEARCH FRONTS - 2008

December 2008



David C. Rubinsztein talks with *ScienceWatch.com* and answers a few questions about this month's Emerging Research Front Paper in the field of Pharmacology & Toxicology.



Article: The roles of intracellular protein-degradation pathways in neurodegeneration

Authors: Rubinsztein, DC

Journal: NATURE, 443 (7113): 780-786 OCT 19 2006

Addresses: Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med Genet, Hills Rd, Cambridge CB2 2XY, England.
 Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 2XY, England.

SW: Why do you think your paper is highly cited?

The aim of the paper was to review the current understanding of the importance of protein degradation pathways in neurodegenerative diseases. This has been a rapidly evolving field and the paper provided the opportunity to include a fairly detailed assessment of more recent data implicating autophagy as an important route for the clearance of aggregate-prone proteins that cause many neurodegenerative diseases.

SW: Does it describe a new discovery, methodology, or synthesis of knowledge?

This was a review which aimed to synthesize and appraise our understanding of the area.

SW: Would you summarize the significance of your paper in layman's terms?

Many neurodegenerative diseases, like **Parkinson's disease** and Huntington's disease, are characterized by the accumulation of specific proteins inside nerve cells in aggregates. Indeed, the relevant proteins show an enhanced propensity to aggregate. Furthermore, many of the aggregate-prone proteins that cause these diseases mediate pathology by a gain-function mechanism—they act as "toxins" to the cells.

While much of the earlier literature was concerned with the factors that influence aggregation specifically, this review considered the importance of pathways that regulate the levels of these "toxins" by influencing their degradation rates—the toxicity of these proteins and the numbers of aggregates that form, correlate with degradation rates. There are now many studies that suggest that impairing the degradation pathways may predispose to neurodegenerative disease, while upregulating specific pathways may be beneficial.

SW: How did you become involved in this research and were any particular problems encountered

"I have been working on Huntington's disease and related conditions for about 16 years."

along the way?

I have been working on Huntington's disease and related conditions for about 16 years. In 2002, we were the first lab to show that one could enhance the degradation of certain intracytoplasmic aggregate-prone proteins, like mutant huntingtin, by upregulating autophagy in cell culture (Ravikumar B, *et al.*, *Hum. Mol. Genet.* 11:1107-17, 2002). Subsequently, we provided proof-of-principle for this approach in transgenic fly and mouse models of the disease (Ravikumar B, *et al.*, *Nature Genetics* 36: 585-95, 2004). The potential of this approach has led to a rapid expansion in our efforts to understand mammalian autophagy in the context of these diseases.

SW: Where do you see your research leading in the future?

My aim is to develop the safest possible ways to be able to enhance the degradation of intracytoplasmic aggregate-prone proteins that cause disease over long periods, as we believe that this would be a rational and potentially plausible therapeutic strategy for a range of neurodegenerative diseases.

SW: Do you foresee any social or political implications for your research?

I would be very happy if we could contribute to helping patients and families with these devastating conditions.

David C. Rubinsztein, M.B. Ch.B., B.Sc. (Hons), Ph.D., FRCPath., FMedSci
Professor of Molecular Neurogenetics
Wellcome Trust Senior Fellow in Clinical Science
Hon Consultant Department of Medical Genetics
Cambridge Institute for Medical Research
University of Cambridge
Cambridge, UK

Keywords: protein degradation pathways in neurodegenerative diseases, aggregate-prone proteins, parkinson's disease, huntington's disease, intracytoplasmic aggregate-prone proteins, mutant huntingtin, upregulating autophagy in cell culture.



[PDF](#)

[back to top](#)

2008 : December 2008 : David C. Rubinsztein

[Scientific Home](#) | [About Scientific](#) | [Site Search](#) | [Site Map](#)

[Copyright Notices](#) | [Terms of Use](#) | [Privacy Statement](#)